<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Arrhythmias during anesthesia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Arrhythmias during anesthesia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Arrhythmias during anesthesia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily Methangkool, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aman Mahajan, MD, PhD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan B Mark, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H981817866">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraoperative tachyarrhythmias (heart rate [HR] &gt;100 beats per minute [bpm]) and bradyarrhythmias (HR &lt;60 bpm) are common; nearly 11 percent of patients experience abnormal HR or rhythm during general anesthesia [
         <a href="#rid1">
          1,2
         </a>
         ]. While most intraoperative arrhythmias are transient and clinically insignificant, some indicate underlying pathology (eg, myocardial ischemia, electrolyte abnormalities), and some are due to a procedure-specific or medication-specific etiology. Occasionally an arrhythmia causes intraoperative hemodynamic instability.
        </p>
        <p>
         This topic reviews common etiologies, recognition, and acute management of intraoperative cardiac arrhythmias. Other topics address life-threatening arrhythmias that require advanced cardiac life support (ACLS) in the perioperative or other settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ACLS
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118690.html" rel="external">
          "Intraoperative advanced cardiac life support (ACLS)"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Further treatment of specific arrhythmias is discussed in additional topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tachyarrhythmias
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1074.html" rel="external">
          "Sinus tachycardia: Evaluation and management"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bradyarrhythmias
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1075.html" rel="external">
          "Sinus bradycardia"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/909.html" rel="external">
          "Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/910.html" rel="external">
          "Second-degree atrioventricular block: Mobitz type II"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/911.html" rel="external">
          "Third-degree (complete) atrioventricular block"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2982643063">
         <span class="h1">
          POTENTIAL CONTRIBUTING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Factors likely to contribute to development of arrhythmias may be identified in the preoperative period, or recognized and managed during the intraoperative period.
        </p>
        <p class="headingAnchor" id="H3147756317">
         <span class="h2">
          Preexisting electrocardiographic (ECG) abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative electrocardiograms (ECGs) are examined when available, and may identify preexisting arrhythmias (eg, atrial fibrillation [AF], premature ventricular contractions [PVCs]) or other abnormal findings that predispose the patient to development of an intraoperative arrhythmia (eg, QTc prolongation, bundle branch block [BBB], Wolff-Parkinson-White [WPW] pattern). A detailed discussion of preoperative ECG evaluation is available in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/94359.html" rel="external">
          "The preoperative ECG: Evaluation and implications for anesthetic management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2448260545">
         <span class="h2">
          Medication effects
         </span>
        </p>
        <p class="headingAnchor" id="H2562116795">
         <span class="h3">
          Medications that increase risk for bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain chronically or acutely administered medications may cause severe bradycardia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative chronotropic agents
         </strong>
         – Beta blockers or other negative chronotropic agents (eg, calcium channel blockers,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ) are the most common cause of drug-induced sinus bradycardia. In a 2019 meta-analysis in noncardiac surgical patients, those receiving beta blockers administered in the perioperative period to prevent surgery-related complications had a higher incidence of clinically significant bradycardia defined as a heart rate (HR) &lt;60 bpm and/or requiring treatment (risk ratio [RR] 2.49, 95% CI 1.74-3.56; 490 studies, 12,239 participants) compared with patients who had none [
         <a href="#rid3">
          3
         </a>
         ]. In that meta-analysis, patients receiving beta blockers also had a higher incidence of hypotension (RR 1.40, 95% CI 1.29-1.51; 49 studies, 12,304 participants).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with ischemic heart disease are often taking these medications chronically, or they may have been administered during the perioperative period. Baseline (admission) HR is noted, and bradycardia is treated only if it is severe (eg, HR &lt;40 beats per minute [bpm]) or associated with evidence of poor systemic perfusion or hemodynamic instability, as noted below. (See
         <a class="local">
          'Pharmacologic treatment of bradycardia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticholinesterase agents
         </strong>
         – Sinus bradycardia may be caused by the muscarinic effects of an acetylcholinesterase inhibitor (eg,
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         or
         <a class="drug drug_general" data-topicid="9403" href="/z/d/drug information/9403.html" rel="external">
          edrophonium
         </a>
         ) when such agents are used to reverse effects of nondepolarizing neuromuscular blocking agents (NMBA) near the end of surgery. The patient should receive an adequate dose of anticholinergic agent (eg,
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         or
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ) when the acetylcholinesterase inhibitor is administered. Underdosing an anticholinergic agent (relative to the acetylcholinesterase inhibitor agent) may lead to severe bradycardia. When this is suspected, repeated doses of glycopyrrolate 0.2 mg or atropine 0.4 mg are appropriate. (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Anticholinesterases'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          Sugammadex
         </a>
         – Severe sinus bradycardia and asystole have been reported after administration of sugammadex for reversal of steroidal NMBA such as
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         . Although this adverse effect of sugammadex is rare, it is potentially life-threatening [
         <a href="#rid4">
          4,5
         </a>
         ]. Particular caution is necessary when sugammadex is given to a patient concurrently receiving medications that may slow the HR (see above). Precautions include slow administration of sugammadex with continuous electrocardiographic monitoring, as well as ensuring immediate availability of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         and positive chronotropic agents (see below). (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'
         </a>
         and
         <a class="local">
          'Pharmacologic treatment of bradycardia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opioids
         </strong>
         – Severe sinus bradycardia may occur when a large bolus dose of an opioid agent (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">
          sufentanil
         </a>
         ) is administered [
         <a href="#rid6">
          6-9
         </a>
         ]. Treatment with small doses of a beta-adrenergic agonist (eg,
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg) and/or an anticholinergic agent (eg,
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         in 0.2 mg increments up to 1 mg or small incremental doses of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         0.2 mg) will typically restore adequate HR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasoconstrictors
         </strong>
         – The carotid baroreceptor reflex response to hypertension may be triggered by administration of a large dose of a vasoconstrictor such as
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         and result in sinus bradycardia  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). This effect tends to be transient, however hemodynamically significant bradycardia may be treated with an anticholinergic agent such as
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3054110465">
         <span class="h3">
          Medications that may prolong the QT interval
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain agents that are commonly administered in the perioperative period may prolong the QT interval (eg,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         (
         <a class="graphic graphic_table graphicRef117757" href="/z/d/graphic/117757.html" rel="external">
          table 2
         </a>
         )) and increase risk for Torsades de pointes (TdP), a malignant ventricular arrhythmia (see
         <a class="local">
          'Polymorphic ventricular tachycardia (torsades de pointes)'
         </a>
         below). Thus, such agents are avoided in patients with a history of prolonged QT interval. (See
         <a class="medical medical_review" href="/z/d/html/94349.html" rel="external">
          "Cardiovascular problems in the post-anesthesia care unit (PACU)", section on 'Ventricular arrhythmias'
         </a>
         .)
        </p>
        <p>
         Although many anesthetic agents (eg, opioids,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , volatile anesthetic agents) may cause mild prolongation of the QT interval (&gt;440 ms), these are unlikely to cause TdP  (
         <a class="graphic graphic_table graphicRef110771" href="/z/d/graphic/110771.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid10">
          10-18
         </a>
         ]. Other causes and potentiators of long QT syndrome are listed in the table  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2104453118">
         <span class="h2">
          Patient-specific factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both atrial and ventricular arrhythmias are more likely to occur under certain abnormal physiologic conditions  (
         <a class="graphic graphic_table graphicRef52416" href="/z/d/graphic/52416.html" rel="external">
          table 5
         </a>
         ). These conditions are treated in the preoperative period when possible, with continuing management during the intraoperative period when indicated.
        </p>
        <p class="headingAnchor" id="H627750164">
         <span class="h3">
          Electrolyte abnormalities
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potassium
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypokalemia – Although there are no definitive values of hypokalemia where elective surgery must be cancelled, potassium &lt;2.5 mmol/L can lead to QT prolongation and increased risk of arrhythmia. Potassium repletion is considered when levels are less than 3.5 mmol/L, typically with 20 mEq over one hour through a central line, or over two hours through a peripheral intravenous (IV) line due to risk of phlebitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hypokalemia is associated with a variety of arrhythmias including premature atrial and ventricular beats, sinus bradycardia, paroxysmal atrial or junctional tachycardia, atrioventricular (AV) block, and ventricular tachycardia (VT) or ventricular fibrillation (VF). Serum potassium levels &lt;3.5 mmol/L predicted serious perioperative arrhythmias and postoperative AF and atrial flutter, and hypokalemic patients undergoing noncardiac surgery experienced a higher frequency of major adverse cardiovascular events compared with controls [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Cardiac arrhythmias and ECG abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hypokalemia often produces characteristic changes on the ECG such as ST segment depression, decreased T wave amplitude, and increased U wave amplitude occurring at the end of the T wave  (
         <a class="graphic graphic_waveform graphicRef73888" href="/z/d/graphic/73888.html" rel="external">
          waveform 1
         </a>
         ), as well as prolongation of the QT interval. However, these changes are not seen in all patients, and there is considerable interpatient variability in the serum potassium concentration associated with progression of either ECG changes or arrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperkalemia – Hyperkalemia can lead to a variety of conduction abnormalities (eg, left bundle branch block [BBB], right BBB, bifascicular block, advanced AV block), as well as sinus bradycardia, sinus arrest, asystole, or VT or VF [
         <a href="#rid21">
          21
         </a>
         ]. Although patients with hyperkalemia may have peaked T waves  (
         <a class="graphic graphic_waveform graphicRef80441" href="/z/d/graphic/80441.html" rel="external">
          waveform 2
         </a>
         ), there is neither an orderly progression of ECG abnormalities seen in individual patients as the potassium rises, nor does the absence of ECG changes preclude life-threatening cardiac arrhythmias associated with hyperkalemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Many patients with preoperative hyperkalemia have end-stage renal disease (ESRD). Preoperative management for patients with or without ESRD depends on the severity of hyperkalemia, as well as on whether the proposed procedure is elective or urgent. Notably,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         should be avoided if potassium ≥5.5 mEq/L. Details regarding management of perioperative hyperkalemic patients are discussed in a separate topic  (
         <a class="graphic graphic_algorithm graphicRef109740" href="/z/d/graphic/109740.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef74169" href="/z/d/graphic/74169.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">
          "Anesthesia for dialysis patients", section on 'Management of hyperkalemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Magnesium
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypomagnesemia – Hypomagnesemia widens the QRS complex and increases the risk of torsades de pointes (TdP), sustained AF, frequent atrial or ventricular ectopic beats, and other ventricular arrhythmias [
         <a href="#rid22">
          22
         </a>
         ]. Clinical manifestations and treatment are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion", section on 'Cardiovascular'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/834.html" rel="external">
          "Hypomagnesemia: Evaluation and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypermagnesemia – Hypermagnesemia (&gt;4 mEq/L) may cause conduction defects, bradycardia, and hypotension. Symptoms typically resolve with cessation of magnesium therapy (eg, IV magnesium infusion for treatment of eclampsia or preeclampsia). In patients with renal insufficiency, isotonic IV fluids plus a loop diuretic (eg,
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         ) are administered, in addition to discontinuing any magnesium therapy. Postoperative dialysis is occasionally necessary. (See
         <a class="medical medical_review" href="/z/d/html/831.html" rel="external">
          "Hypermagnesemia: Causes, symptoms, and treatment", section on 'Cardiovascular effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/831.html" rel="external">
          "Hypermagnesemia: Causes, symptoms, and treatment", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcium
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypocalcemia – Hypocalcemia prolongs the QT interval  (
         <a class="graphic graphic_waveform graphicRef66206" href="/z/d/graphic/66206.html" rel="external">
          waveform 3
         </a>
         ), but has less potential to trigger TdP compared with hypokalemia or hypomagnesemia. Clinical manifestations and treatment of severe acute or symptomatic hypocalcemia by administering IV calcium, as well as treatment of concurrent hypomagnesemia, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/833.html" rel="external">
          "Clinical manifestations of hypocalcemia", section on 'Cardiovascular'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/826.html" rel="external">
          "Treatment of hypocalcemia", section on 'Severe symptomatic and/or acute hypocalcemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercalcemia – Acute hypercalcemia shortens the myocardial action potential, as reflected in a shortened QT interval on the electrocardiogram (ECG). Although moderate hypercalcemia has no clinically important effects on cardiac conduction or the prevalence of supraventricular or ventricular arrhythmias, various cardiac arrhythmias and ST-segment elevation mimicking myocardial infarction have been described with severe hypercalcemia. Treatment is with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         hydration, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/832.html" rel="external">
          "Clinical manifestations of hypercalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/850.html" rel="external">
          "Treatment of hypercalcemia", section on 'Volume expansion with isotonic saline'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3985640544">
         <span class="h3">
          Metabolic and respiratory abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoxemia, hypocarbia or hypercarbia, and acid-base disturbances are contributing factors for arrhythmias. When possible, such abnormalities are corrected. (See
         <a class="medical medical_review" href="/z/d/html/118690.html" rel="external">
          "Intraoperative advanced cardiac life support (ACLS)", section on 'Treat the etiology of the cardiac arrest'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1716397851">
         <span class="h3">
          Intravascular volume depletion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia or dehydration typically results in sinus tachycardia and may lead to development of other arrhythmias.
        </p>
        <p class="headingAnchor" id="H4239724493">
         <span class="h3">
          Myocardial ischemia or failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myocardial ischemia or infarction may be associated with atrial or ventricular arrhythmias including supraventricular tachycardia (SVT), conduction defect, or ectopic ventricular activity. Prevention and management of perioperative myocardial ischemia is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Treatment of ischemia'
         </a>
         .)
        </p>
        <p>
         Patients with moderate or severe right or left ventricular heart failure often have a history of arrhythmias, and may have a biventricular pacemaker for cardiac resynchronization therapy and/or implantable cardioverter defibrillator for antitachycardia therapy. Perioperative management of these devices is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">
          "Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3792762149">
         <span class="h2">
          Procedure-specific factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both atrial and ventricular arrhythmias are more likely during certain types of surgical procedures or other interventions.
        </p>
        <p class="headingAnchor" id="H1819226400">
         <span class="h3">
          Intrathoracic procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         During thoracic surgical procedures performed near the heart (eg, pulmonary or esophageal surgery), contact with cardiac or pulmonary venous structures may cause atrial or ventricular arrhythmias. Prevention and management of arrhythmias that commonly occur during cardiac surgery are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">
          "Management of cardiopulmonary bypass", section on 'Arrhythmias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115472.html" rel="external">
          "Intraoperative problems after cardiopulmonary bypass", section on 'Arrhythmias'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3965673146">
         <span class="h3">
          Intravascular interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient atrial or ventricular arrhythmias commonly occur during insertion of a central venous catheter or pulmonary artery catheter [
         <a href="#rid23">
          23
         </a>
         ]. When the guidewire or catheter enters the right atrium, premature atrial contractions, AF, or other SVTs may occur (see
         <a class="local">
          'Other narrow QRS complex atrial tachyarrhythmias'
         </a>
         below). Upon entry into the right ventricle, right BBB [
         <a href="#rid24">
          24
         </a>
         ] (see
         <a class="local">
          'Bundle branch blocks'
         </a>
         below), PVCs, or VT may occur (see
         <a class="local">
          'Ventricular arrhythmias'
         </a>
         below). For this reason, the ECG is continuously monitored during insertion of such catheters.
        </p>
        <p>
         Other intravascular interventions performed by surgeons or other interventionalists (eg, cardiac catheterization, endovascular revascularization) often cause atrial and/or ventricular arrhythmias.
        </p>
        <p class="headingAnchor" id="H1429768457">
         <span class="h3">
          Electroconvulsive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anesthesia for electroconvulsive therapy (ECT) is associated with various arrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Anesthesia technique'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1709752684">
         <span class="h3">
          Administration of local anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local anesthetic systemic toxicity (LAST) should be suspected whenever physiologic changes, including arrhythmias, occur shortly after administration of a local anesthetic (eg, for a peripheral nerve block). Cardiovascular signs usually occur simultaneously with or shortly after central nervous system symptoms. Typically, tachycardia and hypertension occur, although bradycardia and hypotension have also been described as the first changes. Cardiovascular toxicity can progress to ventricular arrhythmias and/or asystole.
        </p>
        <p>
         Prevention and management of LAST are discussed in detail separately  (
         <a class="graphic graphic_table graphicRef107887" href="/z/d/graphic/107887.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/90613.html" rel="external">
          "Local anesthetic systemic toxicity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3806099833">
         <span class="h1">
          INTRAOPERATIVE DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1282227149">
         <span class="h2">
          Standard electrocardiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         The electrocardiogram (ECG) is continuously monitored for all patients receiving anesthetic agents for sedation, regional anesthesia, or general anesthesia. For those with risk factors for myocardial ischemia, both leads II and V
         <sub>
          5
         </sub>
         are typically used. (See
         <a class="medical medical_review" href="/z/d/html/100067.html" rel="external">
          "Basic patient monitoring during anesthesia", section on 'Electrocardiogram'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Monitoring for myocardial ischemia'
         </a>
         .)
        </p>
        <p>
         If a tachyarrhythmia or bradyarrhythmia develops that cannot be readily diagnosed, all available leads are displayed on the intraoperative monitor and a 12-lead ECG is obtained as soon as feasible.
        </p>
        <p class="headingAnchor" id="H3063513053">
         <span class="h2">
          Recognition of artifacts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Notably, artifact due to electrocautery or pacing spikes can mimic ventricular tachycardia (VT) or ventricular fibrillation (VF). Ventricular-paced rhythms can also mimic VT (see
         <a class="local">
          'Ventricular paced rhythms'
         </a>
         below). Operating room ECG monitors have filtering capability to minimize artifact when set in "monitor" or "filter" mode rather than "diagnostic" mode. However, pacemaker stimulus outputs (ie, pacing spikes) are small-amplitude high-frequency signals that may be attenuated and are not reliably detected. In some cases, detection in the monitor or filter mode is possible in some of the leads, but not in all leads. As a result, most ECG monitors include a "pacing mode" selection that improves detection of paced rhythms by highlighting the pacing spikes.
        </p>
        <p>
         Stable waveforms from the pulse oximeter, intra-arterial catheter, and/or central venous catheter are helpful to distinguish artifact from a true arrhythmia. (See
         <a class="medical medical_review" href="/z/d/html/100067.html" rel="external">
          "Basic patient monitoring during anesthesia", section on 'Sources of ECG artifact'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1702589475">
         <span class="h1">
          BRADYARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of bradyarrhythmias with a heart rate (HR) &lt;60 beats per minute (bpm) depends upon whether the patient is hemodynamically stable or unstable  (
         <a class="graphic graphic_table graphicRef127098" href="/z/d/graphic/127098.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2640139699">
         <span class="h2">
          Sinus bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinus bradycardia with a slow HR &lt;60 bpm but with normal atrial and ventricular depolarization is the most common bradyarrhythmia during anesthesia and surgery  (
         <a class="graphic graphic_waveform graphicRef52675" href="/z/d/graphic/52675.html" rel="external">
          waveform 4
         </a>
         ). Sinus bradycardia due to a variety of conditions such as chronic use of negative chronotropic medications (eg, beta blockers, calcium channel blockers), temporary increases in vagal tone, athletic conditioning, or intrinsic sinus node dysfunction may also occur in other nonsurgical settings.
        </p>
        <p>
         Mild sinus bradycardia (ie, HR 40 to 60 bpm) in a hemodynamically stable patient does not usually require pharmacologic treatment, although the cause may require treatment. (See
         <a class="local">
          'Causes of sinus bradycardia'
         </a>
         below.)
        </p>
        <p>
         Treatment of severe sinus bradycardia associated with hemodynamic instability includes pharmacologic and temporary pacing options. (See
         <a class="local">
          'Pharmacologic treatment of bradycardia'
         </a>
         below and
         <a class="local">
          'Temporary pacing options'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3035914341">
         <span class="h3">
          Causes of sinus bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unique intraoperative causes of sinus bradycardia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vagal reflexes
         </strong>
         – Surgical manipulation may precipitate vagal reflexes that cause bradycardia. Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During eye surgery, the oculocardiac reflex may occur when traction of the extraocular muscles activates a parasympathetic response via the ophthalmic branch of the trigeminal nerve, causing severe bradycardia and even asystole.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During open or laparoscopic abdominal surgery, peritoneal stretching may cause a parasympathetically mediated bradycardia. The surgeon should immediately cease manipulation when these vagal reflexes occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During carotid endarterectomy, removal of carotid plaque may cause stimulation of the carotid sinus nerve resulting in reflex bradycardia and hypotension. Pretreatment with
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         or local infiltration of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         around the nerve and carotid sinus may prevent this reflex.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If HR does not increase when the surgical stimulus is temporarily stopped, an anticholinergic agent is administered. (See
         <a class="local">
          'Pharmacologic treatment of bradycardia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuraxial anesthesia
         </strong>
         – Neuraxial anesthesia with a high T1 to T4 anesthetic level may cause sinus bradycardia and hypotension [
         <a href="#rid25">
          25-28
         </a>
         ]. Optimal treatment of bradycardia caused by blockade of the cardiac accelerator fibers is with beta-adrenergic agonists such as
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         5 to 10 mg or
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         10 to 20 mcg, although
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         may be administered. If bradycardia persists, an epinephrine infusion may be initiated  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). Any epidural infusions should be temporarily discontinued.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, severe bradycardia or asystole associated with hypotension may occur suddenly in an otherwise healthy individual during the course of spinal anesthesia. Immediate treatment with incrementally increased doses of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         is necessary to avoid cardiac arrest (eg, initial bolus of 10 to 20 mcg, then 100 mcg, then a larger bolus dose of 0.5 to 1.0 mg if there is minimal response) [
         <a href="#rid27">
          27-29
         </a>
         ]. This phenomenon is called vasovagal syncope or neurocardiogenic syncope and is also known as the Bezold-Jarisch reflex. Onset of severe bradycardia or asystole is often unanticipated since there is often a delay of 30 minutes or more between administration of the spinal anesthetic and occurrence of such severe cardiovascular depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications
         </strong>
         – Chronically and acutely administered medications that increase risk for sinus bradycardia are discussed above. (See
         <a class="local">
          'Medications that increase risk for bradycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1559514617">
         <span class="h3">
          Pharmacologic treatment of bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinus bradycardia is treated pharmacologically with an intravenous (IV) anticholinergic agent if it is severe with HR &lt;40 bpm, associated with transient episodes of asystole, or if there are signs of inadequate systemic perfusion (eg, electrocardiographic evidence of ischemia) or overt hemodynamic instability.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic instability
         </strong>
         – For hemodynamically unstable patients with sinus bradycardia, IV
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         0.5 mg is administered, and may be repeated every three to five minutes up to a total of 3 mg  (
         <a class="graphic graphic_algorithm graphicRef130748" href="/z/d/graphic/130748.html" rel="external">
          algorithm 2
         </a>
         ). In rare cases, temporary pacing may be necessary. (See
         <a class="local">
          'Temporary pacing options'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic stability
         </strong>
         – For patients who remain hemodynamically stable during severe sinus bradycardia (ie, &lt;40 bpm), we typically administer IV
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         in 0.2 mg increments (up to 1 mg) rather than
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         , in order to avoid undesirable tachycardia, particularly in those with ischemic heart disease. A reasonable alternative is administration of small incremental doses of atropine 0.2 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If bradycardia is associated with hypotension, treatment may include administration of
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         10 to 20 mg. Since tachyphylaxis to ephedrine may occur, another chronotropic agent is typically substituted after 50 to 60 mg have been administered (eg,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         ). For persistent severe bradycardia, continuous infusion of a positive chronotropic agent is typically initiated  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/141346.html" rel="external">
          "Intraoperative use of vasoactive agents", section on 'Vasopressor and positive inotropic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A special circumstance is the patient with a transplanted heart. Due to functional denervation, normal responses to anticholinergic drugs will not typically be effective; instead, a positive chronotropic agent such as
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         (or possibly
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ) is selected. (See
         <a class="medical medical_review" href="/z/d/html/114430.html" rel="external">
          "Anesthesia for heart transplantation", section on 'Denervation of the transplanted heart'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3518.html" rel="external">
          "Heart transplantation in adults: Arrhythmias"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, neither
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         nor
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         is likely to work for bradycardia caused by conduction delays originating below the atrioventricular (AV) node; treatment is described below. (See
         <a class="local">
          'Bundle branch blocks'
         </a>
         below and
         <a class="local">
          'Temporary pacing options'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1218011770">
         <span class="h3">
          Temporary pacing options
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who have recurrent or severe bradycardia with hemodynamic instability, temporary pacing may be necessary (see
         <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">
          "Temporary cardiac pacing"
         </a>
         ). (Temporary pacing is rarely indicated in a hemodynamically stable patient with a HR of 40 to 60 bpm.)
        </p>
        <p>
         Temporary pacing options during the perioperative period include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transcutaneous pacing
         </strong>
         – Transcutaneous pacing is usually the most rapid way to correct bradycardia in the perioperative setting. (See
         <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">
          "Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator", section on 'Placement of transcutaneous pacing/defibrillator pads'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Transcutaneous pads should be placed to the right of the sternum immediately below the clavicle and at the left ventricular apex, usually at the fifth or sixth intercostal space in the midaxillary line, although anterior-posterior pad positioning is an alternative for selected surgical procedures  (
         <a class="graphic graphic_figure graphicRef103268" href="/z/d/graphic/103268.html" rel="external">
          figure 1
         </a>
         ). The pacing mode of an external defibrillator with pacing capability is activated, and the pacing current is increased up to 65 to 100 milliamperes until a stable HR is achieved. Appropriate pacing capture of the myocardium typically results in increased cardiac output and stabilization of hemodynamics. Notably, for patients who are awake or only mildly sedated, transcutaneous pacing may be painful. (See
         <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">
          "Temporary cardiac pacing", section on 'Transcutaneous'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pacing capture may be difficult to achieve in a morbidly obese patient or when appropriate pad placement is not possible (eg, thoracic surgery, lateral or prone position, extensive burns, excessive hair).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transvenous pacing
         </strong>
         – Intraoperative transvenous pacing may be used if transcutaneous pacing fails to reliably capture the myocardium or is not feasible (eg, due to the location of the surgical procedure). Transvenous pacing requires insertion of an introducer sheath in a central vessel, most commonly the right internal jugular vein. This may be impractical once a surgical case is underway, depending on the type of surgery, prior positioning of the patient, and configuration of the sterile surgical drapes. (See
         <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">
          "Temporary cardiac pacing", section on 'Transvenous'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Insertion of the pacing lead requires continuous electrocardiographic (ECG) monitoring due to a high risk for inducing arrhythmias. Correct placement requires expertise in both transvenous wire insertion and pacing technology; thus, cardiology consultation may be required. Ideally, use of fluoroscopy with direct visualization of the pacing lead during insertion will ensure optimal placement within the right ventricle. If intraoperative fluoroscopy is not possible, a postoperative radiograph is necessary to check correct positioning. Notably, a contraindication for transvenous pacing is presence of a mechanical prosthetic tricuspid valve. (See
         <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">
          "Temporary cardiac pacing", section on 'Procedural aspects of temporary transvenous pacing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pacing pulmonary artery catheters
         </strong>
         – Specialized pulmonary artery catheters (PACs) with pacing capability can be used with an external pacemaker. Anesthesiologists are typically familiar with positioning a pacing PAC by employing pressure waveform analysis during insertion. Catheter position can be confirmed with intraoperative transesophageal echocardiography (TEE) and/or a postoperative radiograph. However, the leads within a pacing PAC are typically less stable than those of a dedicated transvenous pacing wire. Other disadvantages of a pacing PAC are similar to those for a transvenous pacing lead (eg, challenges with placement of an introducer sheath in a central vein, contraindication with a mechanical tricuspid valve).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3529130198">
         <span class="h2">
          Other bradyarrhythmias
         </span>
        </p>
        <p class="headingAnchor" id="H2960675349">
         <span class="h3">
          Sinus node dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinus node dysfunction is characterized by a sluggish or absent sinoatrial (SA) nodal pacemaker and/or depressed escape pacemakers in the presence or absence of atrioventricular (AV) nodal conduction disturbances. The patient's HR responses to physiologic demands may be abnormal, and profound sinus bradycardia, sinus pauses, sinus arrest, or nodal exit block may occur.
        </p>
        <p>
         Intraoperative management involves addressing the underlying etiology (eg, drug toxicity from excess calcium channel blockers, beta blockers, or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , or myocardial ischemia). For patients who are hemodynamically unstable,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         may be administered, followed by chronotropic agents such as
         <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">
          isoproterenol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         for continued HR support. For patients who are acutely unstable and in danger of arrest, temporary pacing should be initiated [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/896.html" rel="external">
          "Sinus node dysfunction: Clinical manifestations, diagnosis, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1072.html" rel="external">
          "Sinus node dysfunction: Treatment", section on 'Introduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3721380595">
         <span class="h3">
          Bundle branch blocks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Either a left bundle branch block (BBB)  (
         <a class="graphic graphic_waveform graphicRef61594" href="/z/d/graphic/61594.html" rel="external">
          waveform 5
         </a>
         ), right BBB  (
         <a class="graphic graphic_waveform graphicRef64393" href="/z/d/graphic/64393.html" rel="external">
          waveform 6
         </a>
         ), or fascicular block  (
         <a class="graphic graphic_waveform graphicRef115972" href="/z/d/graphic/115972.html" rel="external">
          waveform 7
         </a>
         and
         <a class="graphic graphic_waveform graphicRef116957" href="/z/d/graphic/116957.html" rel="external">
          waveform 8
         </a>
         ) can occur during anesthesia. New onset of such blocks usually indicates either intrinsic cardiac disease or myocardial ischemia, which should be rapidly addressed.
        </p>
        <p>
         Transient right BBB occasionally occurs during insertion of a PAC, which may lead to complete heart block in a patient with a preexisting left BBB. For this reason, transcutaneous pacing pads should be positioned before PAC insertion for a patient with left BBB.
        </p>
        <p>
         Further treatment of patients with BBB is discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/914.html" rel="external">
          "Left bundle branch block"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/915.html" rel="external">
          "Right bundle branch block"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2106.html" rel="external">
          "Left anterior fascicular block"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2107.html" rel="external">
          "Left posterior fascicular block"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H462169477">
         <span class="h3">
          First, second, or third degree AV block
         </span>
         <span class="headingEndMark">
          —
         </span>
         New onset of perioperative AV block typically occurs in the setting of intrinsic cardiac disease, perioperative ischemia, electrolyte abnormalities, excessive vagal tone, or prior surgical or transcatheter aortic valve replacement. AV block is classified as first, second, or third degree:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First degree AV block occurs when there is delayed but intact conduction from the atria to the ventricles  (
         <a class="graphic graphic_waveform graphicRef67882" href="/z/d/graphic/67882.html" rel="external">
          waveform 9
         </a>
         ), and does not require treatment. (See
         <a class="medical medical_review" href="/z/d/html/913.html" rel="external">
          "First-degree atrioventricular block"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second degree AV block occurs when there is intermittent conduction from the atria to the ventricles, with either progressive prolongation of the PR interval until there is a dropped ventricular beat (Mobitz Type I [Wenckebach]  (
         <a class="graphic graphic_waveform graphicRef73051" href="/z/d/graphic/73051.html" rel="external">
          waveform 10
         </a>
         )); or prolonged PR intervals with occasional dropped ventricular beats (Mobitz Type II  (
         <a class="graphic graphic_waveform graphicRef58649" href="/z/d/graphic/58649.html" rel="external">
          waveform 11
         </a>
         )). Second degree AV block occurring in the perioperative setting may require pacing if bradycardia is severe or causes hemodynamic compromise.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third degree AV block occurs when atrial impulses do not conduct to the ventricles so that P waves are discordant with QRS waves  (
         <a class="graphic graphic_waveform graphicRef72863" href="/z/d/graphic/72863.html" rel="external">
          waveform 12
         </a>
         and
         <a class="graphic graphic_waveform graphicRef126305" href="/z/d/graphic/126305.html" rel="external">
          waveform 13
         </a>
         and
         <a class="graphic graphic_waveform graphicRef132770" href="/z/d/graphic/132770.html" rel="external">
          waveform 14
         </a>
         ). Pacing is typically required since the intrinsic ventricular rhythm is usually very slow (approximately 30 to 40 bpm). (See
         <a class="medical medical_review" href="/z/d/html/911.html" rel="external">
          "Third-degree (complete) atrioventricular block"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2993738974">
         <span class="h2">
          Asystole
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who develop severe intraoperative bradycardia are at risk for progression to asystole or pulseless electrical activity requiring immediate initiation of advanced cardiac life support (ACLS)  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Asystole and pulseless electrical activity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H421153166">
         <span class="h1">
          ATRIAL TACHYARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial tachyarrhythmias with a heart rate (HR) &gt;100 beats per minute (bpm) are classified as having either a narrow QRS complex (QRS duration of &lt;120 ms) or a wide QRS complex (QRS duration &gt;120 ms). (See
         <a class="medical medical_review" href="/z/d/html/943.html" rel="external">
          "Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4049472522">
         <span class="h2">
          Sinus tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sinus tachycardia has a narrow QRS complex and is the most common atrial tachyarrhythmia during anesthesia and surgery. For most patients with mild sinus tachycardia at 100 to 120 bpm, prompt treatment of the underlying cause is adequate. (See
         <a class="local">
          'Causes of sinus tachycardia'
         </a>
         below.)
        </p>
        <p>
         Appropriate treatment of sinus tachycardia requires careful consideration of the most likely cause in order to avoid adverse effects due to inappropriate treatment. For example, administration of beta blockers to a hypovolemic patient may lead to severe hypotension. Another example is a patient who has tachycardia due to sympathetic stimulation, in whom excessive fluid administration may lead to hypervolemia and pulmonary edema.
        </p>
        <p class="headingAnchor" id="H3933906379">
         <span class="h3">
          Causes of sinus tachycardia
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sympathetic stimulation
         </strong>
         – The cause of intraoperative sinus tachycardia accompanied by hypertension is usually sympathetic stimulation in response to pain or other noxious stimuli. Examples include sympathetic responses to laryngoscopy and endotracheal intubation during induction of anesthesia, responses to incision and surgical manipulation during the maintenance phase of anesthesia, or pain and stimulation of airway reflexes during emergence and extubation. Tachycardia due to sympathetic stimulation is treated by increasing doses of intravenous (IV) and/or inhalation anesthetic agents to deepen anesthesia and/or by administering an analgesic agent, similar to treatment of intraoperative hypertension. (See
         <a class="medical medical_review" href="/z/d/html/94532.html" rel="external">
          "Hemodynamic management during anesthesia in adults", section on 'Adjustment of anesthetic depth'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypovolemia or anemia
         </strong>
         – Reflex responses to hypovolemia or anemia cause tachycardia, which is often associated with hypotension. Treatment is administration of appropriate types and volumes of fluid, as discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causes
         </strong>
         – Other causes of intraoperative sinus tachycardia include hypoxemia, hypercarbia, fever, sepsis, or malignant hyperthermia. These etiologies should be identified and treated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2673673540">
         <span class="h3">
          Pharmacologic treatment of tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraoperative sinus tachycardia is usually treated with a short-acting IV beta blocker to decrease HR to &lt;80 bpm if HR is &gt;120 bpm, or at a lower HR if the patient has ischemic heart disease or severe aortic or mitral stenosis. Even short episodes of tachycardia may be associated with significant myocardial ischemia in susceptible patients due to shortening of the diastolic time period for coronary blood flow to the left ventricle (LV) and increased myocardial oxygen demand  (
         <a class="graphic graphic_figure graphicRef94174" href="/z/d/graphic/94174.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef91907" href="/z/d/graphic/91907.html" rel="external">
          table 9
         </a>
         ). Time for LV filling is also diminished with even mild tachycardia. (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Prevention of ischemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease", section on 'Aortic stenosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93514.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with aortic or mitral valve disease", section on 'Mitral stenosis'
         </a>
         .)
        </p>
        <p>
         Typically, bolus doses of
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         20 to 50 mg are administered every two to three minutes. Administration of a cumulative dose of 200 mg should prompt a search for alternative causes of tachycardia.
        </p>
        <p>
         Beta blockers should be avoided in patients with significant hypovolemia or acute hemorrhage causing anemia [
         <a href="#rid31">
          31,32
         </a>
         ], and in those with decompensated heart failure, as noted above. Also, patients with acute or severe bronchospastic lung disease and those with a markedly impaired conduction system (eg, sinus node dysfunction) should not receive beta blockers. (See
         <a class="medical medical_review" href="/z/d/html/141346.html" rel="external">
          "Intraoperative use of vasoactive agents", section on 'Antihypertensive agents'
         </a>
         .)
        </p>
        <p>
         For recurrent tachycardia, options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If beta blocker administration is effective and appropriate, options for treatment of recurrent tachycardia include (see
         <a class="medical medical_review" href="/z/d/html/141346.html" rel="external">
          "Intraoperative use of vasoactive agents", section on 'Antihypertensive agents'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          Esmolol
         </a>
         <strong>
          infusion
         </strong>
         – Esmolol may be administered as a continuous infusion (eg, 50 to 300 mcg/minute). However, infusion of esmolol is usually avoided or another beta blocker is substituted in the immediate postoperative period, since administration of any vasoactive infusion necessitates discharge from the post-anesthesia care unit (PACU) to a monitored setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          Metoprolol
         </a>
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">
          labetalol
         </a>
         – Longer-acting beta blockers such as small bolus doses of metoprolol 1 to 5 mg or labetalol 5 to 10 mg are reasonable alternatives to
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         if intravascular volume status is adequate. Such longer-acting agents are often administered near the end of surgery during preparation for emergence and extubation. Since labetalol is a nonselective beta blocker, it should be titrated in small doses in patients with asthma, chronic obstructive lung disease, heart failure, or hyperadrenergic states such as cocaine or methamphetamine overdose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deepening anesthesia – Adjuvant agents such as opioids or
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         are particularly likely to slow a rapid HR. (See
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Analgesic component: Opioid agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96308.html" rel="external">
          "Maintenance of general anesthesia: Overview", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3891289560">
         <span class="h2">
          Other narrow QRS complex atrial tachyarrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute management of other supraventricular tachycardias (SVTs) with a narrow QRS complex depends on whether the patient is hemodynamically stable  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ). Often, an SVT that is not sinus tachycardia can be terminated with vagal maneuvers or IV pharmacologic therapy  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ). For hemodynamically unstable patients or those with SVT that persists after administration of pharmacologic therapy, electrical cardioversion is attempted if sinus tachycardia has been ruled out [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2381976445">
         <span class="h3">
          Atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF) may occur with sudden onset during or shortly after surgery, or may be chronic  (
         <a class="graphic graphic_waveform graphicRef53988" href="/z/d/graphic/53988.html" rel="external">
          waveform 15
         </a>
         ) [
         <a href="#rid34">
          34,35
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1014.html" rel="external">
          "The electrocardiogram in atrial fibrillation"
         </a>
         ). Perioperative causes that may lead to development of atrial fibrillation should be sought and treated. These include hypovolemia, hypotension, anemia, trauma, and pain, which may increase sympathetic activity, catecholamine release, HR, and arrhythmogenicity [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Treatment of acute or chronic AF with a rapid ventricular response depends on hemodynamic stability  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ). A HR &gt;150 bpm is usually associated with hypotension, while a HR &lt;120 bpm may be well tolerated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic instability with AF and rapid ventricular response (≥120 bpm)
         </strong>
         – Patients with new-onset AF who are hemodynamically unstable (eg, hypotension, myocardial ischemia, pulmonary edema) should undergo immediate synchronized cardioversion  (
         <a class="graphic graphic_figure graphicRef103268" href="/z/d/graphic/103268.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/975.html" rel="external">
          "Basic principles and technique of external electrical cardioversion and defibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic stability with AF and rapid ventricular response (≥120 bpm)
         </strong>
         – Patients with known prior or controlled AF who are hemodynamically stable during AF with a rapid ventricular response may be treated with a beta blocker or a calcium channel blocker for attempted control of HR, rather than with immediate cardioversion. This is often the best option, as patients with chronic AF are at risk for the development of thrombi in the left atrial appendage that may embolize during or after cardioversion. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AF with nonrapid ventricular response (&lt;120 bpm)
         </strong>
         – Patients with AF with a ventricular response &lt;120 bpm are often hemodynamically stable. Those at risk for developing ischemia or hemodynamic instability require pharmacologic control of the ventricular rate  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A beta blocker (eg, bolus doses of
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         10 to 25 mg or
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         1 to 5 mg) may be administered to decrease HR to ≤80 bpm, provided that BP is adequate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration of a calcium channel blocker (eg,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         or
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ) is a reasonable alternative [
         <a href="#rid37">
          37,38
         </a>
         ]. Since both beta blockers and calcium channel blockers have negative inotropic effects, small incremental doses should be employed, and these agents should be avoided in patients with left ventricular systolic failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is commonly used to maintain sinus rhythm after cardioversion and is sometimes selected to slow the ventricular rate in patients who remain in AF.
        </p>
        <p>
        </p>
        <p>
         Notably, in a 2019 meta-analysis, a lower incidence of atrial fibrillation or flutter was found in patients receiving beta blockers administered in the perioperative period to prevent noncardiac surgery-related complications (risk ratio [RR] 0.41, 95% CI 0.21-0.79; nine studies, 9080 participants), although the risk of bradycardia and/or hypotension was increased, compared with patients who did not receive beta blockers [
         <a href="#rid3">
          3
         </a>
         ] (see
         <a class="local">
          'Medications that increase risk for bradycardia'
         </a>
         above). Furthermore, in a 2018 retrospective study of more than surgical patients receiving chronic beta blocker therapy, early resumption of beta blockers on postoperative day one was associated with decreased risk of postoperative atrial fibrillation after noncardiac surgery [
         <a href="#rid39">
          39
         </a>
         ]. Patients receiving
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or statins may also have a lower incidence of perioperative atrial fibrillation compared with controls [
         <a href="#rid40">
          40
         </a>
         ]. However, neither beta blockers nor other pharmacologic agents are used routinely for prophylaxis of atrial arrhythmias.
        </p>
        <p class="headingAnchor" id="H2466304913">
         <span class="h3">
          Atrial flutter
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial flutter typically presents with a rapid ventricular rate (approximately 150 bpm)  (
         <a class="graphic graphic_waveform graphicRef74395" href="/z/d/graphic/74395.html" rel="external">
          waveform 16
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1061.html" rel="external">
          "Electrocardiographic and electrophysiologic features of atrial flutter"
         </a>
         ). Intraoperative treatment depends on whether the patient is hemodynamically stable and is similar to that for AF. (See
         <a class="local">
          'Atrial fibrillation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3322910683">
         <span class="h3">
          Atrioventricular nodal reentrant tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrioventricular (AV) nodal reentrant tachycardia (AVNRT) is a paroxysmal SVT due to a reentry circuit around the AV node  (
         <a class="graphic graphic_waveform graphicRef57001" href="/z/d/graphic/57001.html" rel="external">
          waveform 17
         </a>
         and
         <a class="graphic graphic_waveform graphicRef81639" href="/z/d/graphic/81639.html" rel="external">
          waveform 18
         </a>
         ). Cardioversion should be attempted in a hemodynamically unstable patient who does not respond immediately to vagal maneuvers (such as carotid sinus massage and the Valsalva maneuver) and/or pharmacologic treatment with
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         or a calcium channel blocker  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/902.html" rel="external">
          "Atrioventricular nodal reentrant tachycardia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2498766903">
         <span class="h3">
          Multifocal atrial tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multifocal atrial tachycardia (MAT) is an uncommon arrhythmia that is usually associated with an underlying disorder such as severe pulmonary disease, pulmonary hypertension, coronary artery disease, valvular heart disease, hypomagnesemia, or
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         use. MAT commonly presents with at least three distinct P wave morphologies on ECG, with a rapid, irregular atrial rate of &gt;100 bpm  (
         <a class="graphic graphic_waveform graphicRef127222" href="/z/d/graphic/127222.html" rel="external">
          waveform 19
         </a>
         ). It can be difficult to distinguish MAT from AF. Definitive treatment of MAT relies on addressing the underlying disorder, however in the setting of severe hemodynamic instability antiarrhythmic medications to achieve rate control may be used (eg, beta blockers or calcium channel blockers  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         )). (See
         <a class="medical medical_review" href="/z/d/html/901.html" rel="external">
          "Multifocal atrial tachycardia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3076912183">
         <span class="h3">
          Wide QRS complex atrial tachyarrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wide QRS complex atrial tachyarrhythmias are most often due to aberrant conduction or preexcitation, and more rarely due to medication effect (eg, antiarrhythmics such as
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ) or electrolyte disorders (eg, hyperkalemia). SVT with aberrant conduction is monomorphic with a very regular RR interval. A trial of vagal maneuvers and/or
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         can provide both diagnostic information and may be therapeutic if the wide complex tachycardia resolves. A continuous rhythm strip should be obtained during any intervention that is intended to slow or terminate the SVT.
        </p>
        <p>
         Acute management of wide complex tachycardia depends on whether the patient is hemodynamically stable. Hemodynamic instability may occur with any wide complex tachycardia regardless of etiology, but is more likely if the diagnosis is ventricular tachycardia (VT) rather than an SVT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic instability with wide QRS complex SVT
         </strong>
         – Prompt treatment with electrical cardioversion is necessary to prevent further clinical deterioration or sudden cardiac arrest in a hemodynamically unstable patient. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Regular wide complex'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Irregular wide complex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic stability with wide QRS complex SVT
         </strong>
         – In a stable patient with wide QRS complex SVT known to be supraventricular in origin, management is similar to that for narrow QRS complex SVTs. Expert cardiology consultation is recommended as soon as possible. (See
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management", section on 'Vagal maneuvers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management", section on 'Pharmacologic interventions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For hemodynamically stable patients, additional time may be spent attempting to determine the diagnosis. If the initial diagnosis of wide complex tachycardia was made from a single-lead rhythm strip, a full 12-lead ECG may be useful to rule out VT (see
         <a class="local">
          'Monomorphic ventricular tachycardia'
         </a>
         below), in that the presence of AV dissociation and/or a QRS width ≥0.16 seconds is diagnostic of VT [
         <a href="#rid41">
          41
         </a>
         ]. However, in approximately 10 percent of patients with wide complex tachycardia, a definitive diagnosis of SVT versus VT is difficult to establish. Thus, expert cardiology consultation is obtained as soon as possible [
         <a href="#rid33">
          33,42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2262937916">
         <span class="h4">
          Wolff-Parkinson-White syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with Wolff-Parkinson-White (WPW) syndrome have an AV reciprocating tachycardia (AVRT) due to a macroreentrant circuit that can degenerate into AF  (
         <a class="graphic graphic_waveform graphicRef126303" href="/z/d/graphic/126303.html" rel="external">
          waveform 20
         </a>
         ). During the preoperative consultation for patients with this diagnosis, it is critically important to determine whether the AVRT is orthodromic (with antegrade conduction occurring via the AV node and retrograde conduction via an accessory pathway) or antidromic (with antegrade conduction occurring via the accessory pathway and retrograde conduction via the AV node [or sometimes via a second accessory pathway]) in order to select the correct initial pharmacologic therapy in the event of an intraoperative tachyarrhythmia. Ideally, preoperative consultation includes input from an electrophysiology cardiologist in any patient with known or suspected WPW syndrome. (See
         <a class="medical medical_review" href="/z/d/html/996.html" rel="external">
          "Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Acute treatment of symptomatic arrhythmias'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic instability
         </strong>
         – For hemodynamically unstable patients with known or suspected WPW, treatment is immediate synchronized cardioversion, similar to treatment of SVT due to other etiologies  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SVT with hemodynamic stability
         </strong>
         – For a hemodynamically stable patient, intraoperative management depends on whether conduction is orthodromic or antidromic. However, since it is often difficult to determine if a wide QRS complex tachyarrhythmia has antidromic or orthodromic conduction (and whether it is definitely of supraventricular origin rather than VT), we typically treat stable patients with wide complex tachyarrhythmia with IV
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         in an effort to terminate the tachycardia, or at least slow the ventricular response while awaiting expert cardiology consultation. (See
         <a class="medical medical_review" href="/z/d/html/996.html" rel="external">
          "Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Antidromic AVRT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with orthodromic AVRT may have either a narrow or wide QRS complex. If the complex is narrow or the patient is known to have orthodromic AVRT, initial treatment is one or more vagal maneuvers. If vagal maneuvers are ineffective,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         or
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         may be administered  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/996.html" rel="external">
          "Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Orthodromic AVRT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with antidromic AVRT always have a wide QRS complex tachycardia [
         <a href="#rid43">
          43
         </a>
         ]. Standard AV nodal blocking agents should never be administered (eg, beta blockers, non-dihydropyridine calcium channel blockers [
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ],
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ) if the QRS complex is wide, because blocking the AV node may result in faster conduction of atrial impulses to the ventricle via the accessory pathway, with consequent increase in ventricular rate, exacerbation of hemodynamic instability, and potential for degeneration of the rhythm into lethal VT or ventricular fibrillation (VF) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H445895149">
         <span class="h1">
          VENTRICULAR ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ventricular rhythms have a wide QRS complex (&gt;120 ms). Possible causes should be investigated and treated immediately, with particular attention to the "H's (ie, hypoxia, hypovolemia, acidosis [hydrogen ion], hypo- or hyperkalemia, hypothermia) and T's" (ie, tension pneumothorax, cardiac tamponade, toxins, pulmonary or coronary thrombosis) [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Potential contributing factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/118690.html" rel="external">
          "Intraoperative advanced cardiac life support (ACLS)", section on 'Causes of intraoperative cardiopulmonary arrest'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3667805119">
         <span class="h2">
          Ventricular fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ventricular fibrillation (VF) requires immediate treatment with defibrillation and advanced cardiac life support (ACLS), with repeated shocks as indicated  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_waveform graphicRef118944" href="/z/d/graphic/118944.html" rel="external">
          waveform 21
         </a>
         ). During cardiopulmonary resuscitation (CPR), intravenous (IV)
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         1 mg every three to five minutes is administered, as well as
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         300 mg for the first dose and 150 mg for the second and third doses. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Pulseless ventricular tachycardia and ventricular fibrillation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118690.html" rel="external">
          "Intraoperative advanced cardiac life support (ACLS)", section on 'Initial resuscitation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2861073063">
         <span class="h2">
          Monomorphic ventricular tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ventricular tachycardia (VT) or flutter typically presents with hypotension with or without a pulse. A regular rhythm with a widened QRS complex may be monomorphic VT  (
         <a class="graphic graphic_waveform graphicRef63176" href="/z/d/graphic/63176.html" rel="external">
          waveform 22
         </a>
         ) or ventricular flutter  (
         <a class="graphic graphic_waveform graphicRef65800" href="/z/d/graphic/65800.html" rel="external">
          waveform 23
         </a>
         ).
         <em>
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/920.html" rel="external">
          "Wide QRS complex tachycardias: Approach to the diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulseless ventricular tachycardia
         </strong>
         – VT with a diminished pulse visible with intra-arterial monitoring requires immediate synchronized cardioversion and ACLS, while patients with no visible or palpable pulse require defibrillation and ACLS  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Regular wide complex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ventricular tachycardia with a pulse
         </strong>
         – VT with a pulse may be treated with synchronized cardioversion  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If necessary, myocardial perfusion is augmented with infusion of a vasoconstrictor such as
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">
          vasopressin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         ) .
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          Epinephrine
         </a>
         is generally avoided due to possible exacerbation of myocardial ischemia, but if selected, the infusion should be titrated to effect to avoid tachycardia. Once blood pressure is adequate,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         may be administered to reduce the frequency of VT. (See
         <a class="medical medical_review" href="/z/d/html/101641.html" rel="external">
          "Wide QRS complex tachycardias: Approach to management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1295873706">
         <span class="h2">
          Polymorphic ventricular tachycardia (torsades de pointes)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Torsades de pointes (TdP) is an irregular polymorphic VT  (
         <a class="graphic graphic_waveform graphicRef53891" href="/z/d/graphic/53891.html" rel="external">
          waveform 24
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic instability
         </strong>
         – Prompt defibrillation and ACLS is indicated for TdP causing pulselessness, but synchronized cardioversion may be attempted if a diminished pulse is visible with intra-arterial monitoring  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Irregular wide complex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamic stability
         </strong>
         – For a hemodynamically stable patient having recurrent episodes of TdP, first-line therapy in the perioperative period is administration of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         2 grams as a slow IV bolus. Temporary transvenous overdrive pacing (atrial or ventricular) at approximately 100 beats per minute (bpm) is generally reserved for patients with TdP associated with long QT syndrome if there is no response to IV magnesium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cardiology consultation is obtained as soon as possible, similar to management of other wide QRS complex tachycardias. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/936.html" rel="external">
          "Overview of the acute management of tachyarrhythmias", section on 'Polymorphic ventricular tachycardia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3692319689">
         <span class="h2">
          Other ventricular arrhythmias
         </span>
        </p>
        <p class="headingAnchor" id="H2860926012">
         <span class="h3">
          Premature ventricular contractions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Premature ventricular contractions (PVCs) are common in the general population, even in patients without cardiac disease  (
         <a class="graphic graphic_waveform graphicRef57511" href="/z/d/graphic/57511.html" rel="external">
          waveform 25
         </a>
         ). Isolated PVCs are usually clinically insignificant, particularly if they occur in a healthy surgical patient due to increased sympathetic stimulation. Frequent PVCs may be a sign of myocardial ischemia or electrolyte abnormalities. These conditions should be suspected as contributing factors and treated if confirmed, particularly in patients with cardiovascular comorbidities (eg, hypertension, ischemic heart disease, systolic or diastolic heart failure, hypertrophic cardiomyopathy). (See
         <a class="medical medical_review" href="/z/d/html/994.html" rel="external">
          "Premature ventricular complexes: Clinical presentation and diagnostic evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3679065249">
         <span class="h3">
          Nonsustained ventricular tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonsustained VT is diagnosed when three or more consecutive ventricular beats are noted on the ECG, at a rate &gt;120 bpm but lasting &lt;30 seconds  (
         <a class="graphic graphic_waveform graphicRef73299" href="/z/d/graphic/73299.html" rel="external">
          waveform 26
         </a>
         ).
        </p>
        <p>
         For hemodynamically stable patients with nonsustained VT who have a heart rate (HR) &gt;100 bpm but no compromise of cardiac function, a beta blocker or calcium channel blocker may be administered to reduce the ventricular rate  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ).
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         or class IB antiarrhythmic agents (eg,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ) may also be effective to maintain sinus rhythm. Similar to patients with PVCs, electrolyte abnormalities and myocardial ischemia should be suspected and treated. We continue electrocardiographic monitoring during the intraoperative and postoperative periods since degeneration into a nonperfusing rhythm (eg, VT or VF) may occur. Further management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/917.html" rel="external">
          "Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3505150958">
         <span class="h3">
          Ventricular paced rhythms
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the setting of a supraventricular tachycardia (SVT) in a patient with a pacemaker, the pacemaker may "track" the atrial rate and pace the ventricle with the same rate. This may appear similar to VT on the electrocardiogram (ECG), particularly if the rate is rapid  (
         <a class="graphic graphic_waveform graphicRef126304" href="/z/d/graphic/126304.html" rel="external">
          waveform 27
         </a>
         ). It is also possible for a pacemaker to cause retrograde conduction that passes from the ventricle to the atrium, and then conducts again to the ventricle, resulting in an endless loop tachycardia with a wide QRS complex.
        </p>
        <p>
         To achieve a normal ventricular rate, it may be necessary to reset the pacemaker to an asynchronous mode (at a lower rate) with a magnet or a programming machine. (See
         <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">
          "Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator", section on 'Magnet application'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94293.html" rel="external">
          "Perioperative management of patients with a pacemaker or implantable cardioverter-defibrillator", section on 'Reprogramming with a programming machine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3216529387">
         <span class="h1">
          POSTOPERATIVE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The electrocardiogram (ECG) is continuously monitored in the post-anesthesia care unit (PACU) in all patients, but this is especially important for those who developed an arrhythmia during anesthesia and surgery.
        </p>
        <p>
         A cardiology consultation should be obtained for patients with evidence of myocardial ischemia (see
         <a class="medical medical_review" href="/z/d/html/69.html" rel="external">
          "Perioperative myocardial infarction or injury after noncardiac surgery"
         </a>
         ), as well as those who developed a persistent or clinically significant arrhythmia (eg, new onset atrial fibrillation [AF], second or third degree atrioventricular [AV] block, ventricular tachycardia [VT]) or required pharmacologic or other treatment (eg, infusion of an antiarrhythmic agent, pacing, cardioversion) during the intraoperative period.
        </p>
        <p>
         Patients who had self-limited arrhythmias such as sinus tachycardia, sinus bradycardia, first degree AV block, or premature ventricular contractions (PVCs) usually do not need a postoperative cardiology consultation, particularly if they did not require treatment for hemodynamic instability. In most of these cases, inciting causes are easily corrected and have often resolved by the time the patient arrives in the PACU.
        </p>
        <p class="headingAnchor" id="H1116023503">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117075.html" rel="external">
          "Society guideline links: Basic and advanced cardiac life support in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H754484273">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contributing factors
         </strong>
         – Factors contributing to development of arrhythmias may include (see
         <a class="local">
          'Potential contributing factors'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preexisting abnormalities
         </strong>
         – Preexisting arrhythmias or other abnormal findings on the electrocardiogram (ECG).(See
         <a class="local">
          'Preexisting electrocardiographic (ECG) abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Medication effects
         </strong>
         – Certain medications that increase risk for bradycardia or prolong the QT interval. (See
         <a class="local">
          'Medication effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patient-specific factors
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Electrolyte abnormalities (See
         <a class="local">
          'Electrolyte abnormalities'
         </a>
         above.)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hypoxemia, hypocarbia or hypercarbia, acid-base disturbances (See
         <a class="local">
          'Metabolic and respiratory abnormalities'
         </a>
         above.)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intravascular volume depletion (See
         <a class="local">
          'Intravascular volume depletion'
         </a>
         above.)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Myocardial ischemia or failure (See
         <a class="local">
          'Myocardial ischemia or failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Procedure-specific factors
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intrathoracic procedures (See
         <a class="local">
          'Intrathoracic procedures'
         </a>
         above.)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intravascular interventions (See
         <a class="local">
          'Intravascular interventions'
         </a>
         above.)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Electroconvulsive therapy (ECT) (See
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         above.)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Local anesthetic systemic toxicity (LAST)  (
         <a class="graphic graphic_table graphicRef107887" href="/z/d/graphic/107887.html" rel="external">
          table 7
         </a>
         ) (See
         <a class="local">
          'Administration of local anesthetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – If a perioperative arrhythmia cannot be readily diagnosed, all available leads are displayed on the monitor, and a 12-lead ECG is obtained. Notably, artifact due to electrocautery or pacing spikes can mimic ventricular tachycardia (VT) or ventricular fibrillation (VF). Stable waveforms from the pulse oximeter, intra-arterial catheter, and/or central venous catheter may be helpful to distinguish artifact from a true arrhythmia. (See
         <a class="local">
          'Intraoperative diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of bradyarrhythmias
         </strong>
         – Bradyarrhythmias with heart rate (HR) &lt;60 bpm include  (
         <a class="graphic graphic_table graphicRef127098" href="/z/d/graphic/127098.html" rel="external">
          table 8
         </a>
         ) (see
         <a class="local">
          'Bradyarrhythmias'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sinus bradycardia
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Mild sinus bradycardia
         </strong>
         – Bradycardia with HR 40 to 60 bpm with normal atrial and ventricular depolarization in a hemodynamically stable patient does not usually require pharmacologic treatment. Causes are sought and treated. (See
         <a class="local">
          'Causes of sinus bradycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Severe sinus bradycardia
         </strong>
         – Bradycardia with HR &lt;40 bpm is treated with intravenous (IV) anticholinesterase agents (eg,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         0.5 mg for hemodynamically unstable patients, with repeated doses every three to five minutes up to a total of 3 mg  (
         <a class="graphic graphic_algorithm graphicRef130748" href="/z/d/graphic/130748.html" rel="external">
          algorithm 2
         </a>
         ), or IV
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         0.2 mg for hemodynamically stable patients, with repeated doses up to 1 mg). Further treatment of associated hypotension may include
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         10 to 20 mg as bolus doses, or a continuous infusion of a positive chronotropic agent (eg,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 1
         </a>
         )). (See
         <a class="local">
          'Pharmacologic treatment of bradycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In some cases, a temporary pacing option may be necessary (eg, transcutaneous, transvenous, transesophageal, or pulmonary artery catheter with pacing capabilities). (See
         <a class="local">
          'Temporary pacing options'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atrioventricular (AV) block
         </strong>
         – First degree AV block does not require treatment. Second degree AV block may require pacing if bradycardia is severe or causes hemodynamic compromise. Third degree AV block usually requires pacing due to a very slow HR (ie, 30 to 40 bpm). (See
         <a class="local">
          'First, second, or third degree AV block'
         </a>
         above.):
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supraventricular tachyarrhythmias (SVTs)
         </strong>
         – SVTs with a narrow QRS complex (QRS duration &lt;120 ms) include (see
         <a class="local">
          'Atrial tachyarrhythmias'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sinus tachycardia
         </strong>
         – For sinus tachycardia with HR 100 to 120 beats per minute [bpm]), prompt treatment of the underlying cause (eg, inadequate anesthesia and/or analgesia, hypovolemia, anemia) is usually adequate. For patients with HR &gt;120 bpm or ischemic heart disease, an IV beta blocker is typically administered to decrease HR to &lt;80 bpm. (See
         <a class="local">
          'Sinus tachycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other narrow QRS complex SVTs
         </strong>
         – Treatment depends on whether the patient is hemodynamically stable  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ). Ventricular rate &gt;150 bpm is usually associated with hypotension, while a ventricular rate &lt;120 bpm may be well tolerated. (See
         <a class="local">
          'Other narrow QRS complex atrial tachyarrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Atrial fibrillation or flutter
         </strong>
         (see
         <a class="local">
          'Atrial fibrillation'
         </a>
         above and
         <a class="local">
          'Atrial flutter'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For hemodynamically unstable patients with new-onset atrial fibrillation (AF) or flutter, treatment is immediate synchronized cardioversion  (
         <a class="graphic graphic_figure graphicRef103268" href="/z/d/graphic/103268.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For hemodynamically stable patients with preexisting AF who develop a rapid ventricular response or those with HR &lt;120 bpm, IV beta blockers (eg,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         ) or calcium channel blockers (eg,
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ) may control HR  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ), rather than employing immediate cardioversion (with exposure to risk for atrial thrombus embolization).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          AV nodal reentrant tachycardia (AVNRT)
         </strong>
         – For hemodynamically unstable patients who do not respond immediately to vagal maneuvers (such as carotid sinus massage and the Valsalva maneuver) and/or pharmacologic treatment with
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         or a calcium channel blocker  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         ), cardioversion should be attempted. (See
         <a class="local">
          'Atrioventricular nodal reentrant tachycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Multifocal atrial tachycardia (MAT)
         </strong>
         – For a rapid ventricular response, pharmacologic agents are administered to achieve rate control (eg, IV beta blockers or calcium channel blockers  (
         <a class="graphic graphic_table graphicRef110671" href="/z/d/graphic/110671.html" rel="external">
          table 10
         </a>
         )). (See
         <a class="local">
          'Multifocal atrial tachycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SVTs with a wide QRS complex
         </strong>
         – SVTs with QRS duration &gt;120 ms include (see
         <a class="local">
          'Wide QRS complex atrial tachyarrhythmias'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          SVT with aberrant conduction
         </strong>
         – Monomorphic wide complex SVT often responds to a trial of vagal maneuvers and/or
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         . Further management is similar to that for narrow QRS complex SVTs in a stable patient with a SVT known to be supraventricular in origin  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ). (See
         <a class="local">
          'Wide QRS complex atrial tachyarrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Wolff-Parkinson-White (WPW) syndrome
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For hemodynamically unstable patients with known or suspected WPW syndrome, we typically treat with IV
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         to terminate the tachycardia or slow the ventricular response, particularly if it is difficult to determine whether conduction is orthodromic (ie, through the AV node) or antidromic (ie, via an accessory pathway), or whether the arrhythmia might actually be VT rather than SVT.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For hemodynamically stable patients with suspected WPW syndrome, standard AV nodal blocking agents (ie, beta blockers, calcium channel blockers,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">
          adenosine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ) should
         <strong>
          NOT
         </strong>
         be administered unless it is known that conduction is orthodromic. Risks for blocking the AV node in a patient with antidromic conduction include faster conduction of atrial impulses to the ventricle with increased ventricular rate, hemodynamic instability, or rhythm degeneration into VT or VF. (See
         <a class="local">
          'Wolff-Parkinson-White syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ventricular rhythms
         </strong>
         (see
         <a class="local">
          'Ventricular arrhythmias'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulseless VF or VT
         </strong>
         (see
         <a class="local">
          'Ventricular fibrillation'
         </a>
         above and
         <a class="local">
          'Monomorphic ventricular tachycardia'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         VF or VT with no visible or palpable pulse is treated with immediate defibrillation and advanced cardiac life support (ACLS), with repeated shocks as indicated  (
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         VT with a pulse, even if diminished, may be treated with synchronized cardioversion  (
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Torsades de pointes (TdP)
         </strong>
         (see
         <a class="local">
          'Polymorphic ventricular tachycardia (torsades de pointes)'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For TdP without a pulse, prompt defibrillation and ACLS are indicated  (
         <a class="graphic graphic_waveform graphicRef53891" href="/z/d/graphic/53891.html" rel="external">
          waveform 24
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For a hemodynamically unstable patient with a diminished pulse (eg, visible with intra-arterial monitoring), synchronized cardioversion may be attempted  (
         <a class="graphic graphic_waveform graphicRef53891" href="/z/d/graphic/53891.html" rel="external">
          waveform 24
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">
          algorithm 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">
          algorithm 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For a hemodynamically stable patient with recurrent intraoperative episodes of TdP, first-line therapy is administration of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         2 g as a slow IV bolus. Temporary transvenous overdrive pacing (atrial or ventricular) at approximately 100 bpm is generally reserved for patients with TdP associated with long QT syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other ventricular arrhythmias
         </strong>
         – Frequent premature ventricular contractions (PVCs), nonsustained VT, monomorphic VT, and ventricular paced rhythms are not immediately life-threatening. (See
         <a class="local">
          'Other ventricular arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative management
         </strong>
         – In the post-anesthesia care unit (PACU), the ECG is continuously monitored and a cardiology consultation is obtained for patients with persistent or clinically significant arrhythmia (eg, new onset of AF, second or third degree AV block, VT), suspected myocardial ischemia, or if intraoperative pharmacologic or other treatment (eg, infusion of an antiarrhythmic agent, pacing, cardioversion) was necessary. (See
         <a class="local">
          'Postoperative management'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Forrest JB, Cahalan MK, Rehder K, et al. Multicenter study of general anesthesia. II. Results. Anesthesiology 1990; 72:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forrest JB, Rehder K, Cahalan MK, Goldsmith CH. Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes. Anesthesiology 1992; 76:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blessberger H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev 2019; 9:CD013438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhavani SS. Severe bradycardia and asystole after sugammadex. Br J Anaesth 2018; 121:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter JM, Naguib M. Sugammadex-induced bradycardia and asystole: how great is the risk? Br J Anaesth 2018; 121:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu W, Bidwai AV, Stanley TH, Isern-Amaral J. Cardiovascular dynamics after large doses of fentanyl and fentanyl plus N2O in the dog. Anesth Analg 1976; 55:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash O, Verdouw PD, de Jong JW, et al. Haemodynamic and biochemical variables after induction of anaesthesia with fentanyl and nitrous oxide in patients undergoing coronary artery by-pass surgery. Can Anaesth Soc J 1980; 27:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeSouza G, Lewis MC, TerRiet MF. Severe bradycardia after remifentanil. Anesthesiology 1997; 87:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gravlee GP, Ramsey FM, Roy RC, et al. Rapid administration of a narcotic and neuromuscular blocker: a hemodynamic comparison of fentanyl, sufentanil, pancuronium, and vecuronium. Anesth Analg 1988; 67:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lischke V, Wilke HJ, Probst S, et al. Prolongation of the QT-interval during induction of anesthesia in patients with coronary artery disease. Acta Anaesthesiol Scand 1994; 38:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korpinen R, Saarnivaara L, Siren K. QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol. Acta Anaesthesiol Scand 1995; 39:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaballos M, Jimeno C, Almendral J, et al. Cardiac electrophysiological effects of remifentanil: study in a closed-chest porcine model. Br J Anaesth 2009; 103:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaloudis DG, Kanakoudis FS, Xatzikraniotis A, Bischiniotis TS. The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans. Eur J Anaesthesiol 1995; 12:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaloudis DG, Kanakoudis FS, Petrou AM, et al. The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans. Eur J Anaesthesiol 1996; 13:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saarnivaara L, Klemola UM, Lindgren L, et al. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia. Acta Anaesthesiol Scand 1990; 34:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saarnivaara L, Klemola UM, Lindgren L. QT interval of the ECG, heart rate and arterial pressure using five non-depolarizing muscle relaxants for intubation. Acta Anaesthesiol Scand 1988; 32:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Kam PJ, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig 2010; 30:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owczuk R, Wujtewicz MA, Sawicka W, et al. The effect of intravenous lidocaine on QT changes during tracheal intubation. Anaesthesia 2008; 63:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahr JA, Parks R, Boisvert D, et al. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA 1999; 281:2203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora P, Pourafkari L, Visnjevac O, et al. Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery. Clin Chem Lab Med 2017; 55:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000; 18:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013; 127:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodzic S, Golic D, Smajic J, et al. Complications Related to Insertion and Use of Central Venous Catheters (CVC). Med Arch 2014; 68:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprung CL, Elser B, Schein RM, et al. Risk of right bundle-branch block and complete heart block during pulmonary artery catheterization. Crit Care Med 1989; 17:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratadour P, Viale JP, Parlow J, et al. Sympathovagal effects of spinal anesthesia assessed by the spontaneous cardiac baroreflex. Anesthesiology 1997; 87:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesser JB, Sanborn KV, Valskys R, Kuroda M. Severe bradycardia during spinal and epidural anesthesia recorded by an anesthesia information management system. Anesthesiology 2003; 99:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caplan RA, Ward RJ, Posner K, Cheney FW. Unexpected cardiac arrest during spinal anesthesia: a closed claims analysis of predisposing factors. Anesthesiology 1988; 68:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keats AS. Anesthesia mortality--a new mechanism. Anesthesiology 1988; 68:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinsella SM, Tuckey JP. Perioperative bradycardia and asystole: relationship to vasovagal syncope and the Bezold-Jarisch reflex. Br J Anaesth 2001; 86:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74:e51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beattie WS, Wijeysundera DN, Karkouti K, et al. Acute surgical anemia influences the cardioprotective effects of beta-blockade: a single-center, propensity-matched cohort study. Anesthesiology 2010; 112:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ragoonanan TE, Beattie WS, Mazer CD, et al. Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats. Anesthesiology 2009; 111:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhave PD, Goldman LE, Vittinghoff E, et al. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J 2012; 164:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danelich IM, Lose JM, Wright SS, et al. Practical management of postoperative atrial fibrillation after noncardiac surgery. J Am Coll Surg 2014; 219:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karamchandani K, Khanna AK, Bose S, et al. Atrial Fibrillation: Current Evidence and Management Strategies During the Perioperative Period. Anesth Analg 2020; 130:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Writing Group Members, January CT, Wann LS, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2019; 16:e66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna AK, Naylor DF Jr, Naylor AJ, et al. Early Resumption of β Blockers Is Associated with Decreased Atrial Fibrillation after Noncardiothoracic and Nonvascular Surgery: A Cohort Analysis. Anesthesiology 2018; 129:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oesterle A, Weber B, Tung R, et al. Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis. Am J Med 2018; 131:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drew BJ, Scheinman MM. ECG criteria to distinguish between aberrantly conducted supraventricular tachycardia and ventricular tachycardia: practical aspects for the immediate care setting. Pacing Clin Electrophysiol 1995; 18:2194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bengali R, Wellens HJ, Jiang Y. Perioperative management of the Wolff-Parkinson-White syndrome. J Cardiothorac Vasc Anesth 2014; 28:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim RJ, Gerling BR, Kono AT, Greenberg ML. Precipitation of ventricular fibrillation by intravenous diltiazem and metoprolol in a young patient with occult Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 2008; 31:776.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 94357 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2405739" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Multicenter study of general anesthesia. II. Results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1729933" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31556094" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29935601" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Severe bradycardia and asystole after sugammadex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29935599" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sugammadex-induced bradycardia and asystole: how great is the risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/943974" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cardiovascular dynamics after large doses of fentanyl and fentanyl plus N2O in the dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6966530" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Haemodynamic and biochemical variables after induction of anaesthesia with fentanyl and nitrous oxide in patients undergoing coronary artery by-pass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9357922" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Severe bradycardia after remifentanil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2892437" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Rapid administration of a narcotic and neuromuscular blocker: a hemodynamic comparison of fentanyl, sufentanil, pancuronium, and vecuronium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8171949" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prolongation of the QT-interval during induction of anesthesia in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7484039" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : QT interval of the ECG, heart rate and arterial pressure during anaesthetic induction: comparative effects of alfentanil and esmolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19457895" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cardiac electrophysiological effects of remifentanil: study in a closed-chest porcine model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8665880" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8842657" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The effects of midazolam or propofol followed by suxamethonium on the QT interval in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2343728" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2905566" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : QT interval of the ECG, heart rate and arterial pressure using five non-depolarizing muscle relaxants for intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20568829" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18547294" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The effect of intravenous lidocaine on QT changes during tracheal intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10376573" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27107837" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11043630" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Electrocardiographic manifestations of hyperkalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23172839" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25568558" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Complications Related to Insertion and Use of Central Venous Catheters (CVC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2909309" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risk of right bundle-branch block and complete heart block during pulmonary artery catheterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9416721" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Sympathovagal effects of spinal anesthesia assessed by the spontaneous cardiac baroreflex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14508318" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Severe bradycardia during spinal and epidural anesthesia recorded by an anesthesia information management system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337390" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Unexpected cardiac arrest during spinal anesthesia: a closed claims analysis of predisposing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337388" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Anesthesia mortality--a new mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11573596" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Perioperative bradycardia and asystole: relationship to vasovagal syncope and the Bezold-Jarisch reflex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30412709" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032700" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute surgical anemia influences the cardioprotective effects of beta-blockade: a single-center, propensity-matched cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19809291" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Metoprolol reduces cerebral tissue oxygen tension after acute hemodilution in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26472995" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23194493" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25127508" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Practical management of postoperative atrial fibrillation after noncardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31569164" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Atrial Fibrillation: Current Evidence and Management Strategies During the Perioperative Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30703530" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30300157" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Early Resumption ofβBlockers Is Associated with Decreased Atrial Fibrillation after Noncardiothoracic and Nonvascular Surgery: A Cohort Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29476748" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8771133" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : ECG criteria to distinguish between aberrantly conducted supraventricular tachycardia and ventricular tachycardia: practical aspects for the immediate care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20956222" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25027102" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Perioperative management of the Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18507555" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Precipitation of ventricular fibrillation by intravenous diltiazem and metoprolol in a young patient with occult Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
